The Good, The Bad, And The Uncertain: Trump’s Second Administration And The Rx Industry

 
• By Nielsen Hobbs

The pharma industry arguably suffered none of the possible downside risks during the first Trump Administration, but its relationship with Biden could not have been much worse. And while sponsors may hope a Trump return could improve their fortunes, having Robert F. Kennedy Jr. supervising the FDA is likely not the prescription they prefer.

With Trump’s return, pharma trades a disagreeable White House for an unpredictable one. (Shutterstock)

More from Elections

More from Legislation